Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3215]

Landmark UK survey of blood cancer patients' needs is launched

Landmark UK survey of blood cancer patients' needs is launched

EHA 2014: Azacitidine improves median overall surival for AML over standard regimens

EHA 2014: Azacitidine improves median overall surival for AML over standard regimens

Lipids help to fight leukaemia

Lipids help to fight leukaemia

EHA 2014: Gdf -11 a new target to improve anaemia in thalassemia

EHA 2014: Gdf -11 a new target to improve anaemia in thalassemia

EHA 2014: Treatment of acute lymphoblastic leukaemia by activation of patient's immune cells by a bispecific antibody

EHA 2014: Treatment of acute lymphoblastic leukaemia by activation of patient's immune cells by a bispecific...

EHA 2014: Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish patients

EHA 2014: Do generics of imatinib jeopardize patient safety for the sake of saving money? An experience in Turkish...

EHA 2014: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL

EHA 2014: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in...

EHA 2014: Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows

EHA 2014: Ibrutinib improves survival in CLL and SLL patients, RESONATE study shows

Resurrecting immunity against tumours

Resurrecting immunity against tumours

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

ASCO 2014: Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL

More from ecancer